Quoin raises $16.6M upfront in PIPE; up to $104.6M total with milestone warrants

Quoin Pharmaceuticals, Ltd.

Upfront gross proceeds of $16.6M ($15M net) from private placement; proceeds for QRX003 development and general corporate.
Warrant series H, I, J, K with exercise prices $9.075-$12.375 per ADS; potential cash proceeds up to $88M if exercised.
Investors include AIGH Capital, Soleus Capital, Nantahala Capital, Diadema, Stonepine, ADAR1, Velan; director Langer invested $128k.
Warrant exercise triggers tied to FDA milestones for QRX003: Type C meeting, pivotal trial endpoints, FDA approval, or PRV sale.
Directors and officers subject to 180-day lock-up; proceeds with warrant exercise expected to fund operations into 2027.

Key facts

Extracted from this filing and checked against the source text.

Equity Issuances SEC 8-K Item 3.02/3.03 confidence 0.99

Quoin Pharmaceuticals, Ltd. issued 15,152 ADSs representing ordinary shares, Pre-Funded Warrants to purchase 1,993,939 ADSs, Series H Warrants to purchase 2,009,091 ADSs, Series I Warrants to pur of unit to institutional and accredited investors for aggregate upfront gross proceeds of approximately $16.6 million (combined purchase price of $8.25 per unit or $8.2499 for pre-funded unit).

Security: unit
Shares: 15,152 ADSs representing ordinary shares, Pre-Funded Warrants to purchase 1,993,939 ADSs, Series H Warrants to purchase 2,009,091 ADSs, Series I Warrants to pur
Purchaser: institutional and accredited investors
Consideration: aggregate upfront gross proceeds of approximately $16.6 million (combined purchase price of $8.25 per unit or $8.2499 for pre-funded unit)

Exact text from the filing

On October 10, 2025, Quoin Pharmaceuticals Ltd. (the "Company" or "Quoin") entered into a Securities Purchase Agreement (the "Purchase Agreement") with several institutional and accredited investors (the "Purchasers") for the issuance and sale in a private placement (the "Private Placement") of securities for gross proceeds at the Closing Date (as defined below) of approximately $16.6 million.

View on SEC.gov

Browse all equity issuances →

Quoin Pharmaceuticals, Ltd. filing history →

Source: SEC EDGAR

accession 0001104659-25-099735

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.